News

In October, Novartis expects to launch Tasigna for the treatment of chronic myeloid leukemia in adults who have developed resistance or intolerance to at least one prior therapy, including imatinib.

Bayer's Xarelto (rivaroxaban 10 mg tablets) is the second new oral anticoagulant to be marketed in Canada this year, following the introduction of Boehringer Ingelheim's Pradax (dabigatran etexilate 75 mg and 110 mg capsules) in July.